Health & Biotech
Creso posts nearly $1m in six-month revenue ahead of acquisition
Cannabis: Althea turns focus to Canada with new acquisition
Health: Orthocell’s technology could be even more powerful than first thought
Could cannabinoids be the answer to aggressive brain cancer?
Amplia Therapeutics’ drugs excel in study, CEO wants clinical development ASAP
Expert view: Here are 3 things we learned about where the cannabis industry is headed
Health: Patrys takes another step towards clinical trials for cancer-fighting tech
Dr Boreham’s Crucible: Pharmaxis shareholders breathe easy – the FDA loves you
Is dentistry that lucrative? ASX dental stocks in 2019 says ‘only for equipment makers’
Pot for pets – yes, it’s a thing. But best not to think of it as ‘pot’
Health: Adherium announces it’s clear to enter the US; shares climb 19 pc
Dr Boreham’s Crucible: Nuheara’s still got its ear to the ground for a suitor… but does it actually need one?
Cash-flow surge: MGC Pharma boosts outlook as revenue accelerates in the June quarter
Biotron to host international HIV experts after deep-diving into its data
TGA review of breast implants has AirXpanders going flat
Pot: THC Global has landed its manufacturing licence for Southport
Palla is sticking with opioids, says no thanks to pot
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
